The success has brought Biontech a huge leap in sales and profits

The success of its corona vaccine has brought the Mainz company Biontech a huge leap in sales and profits. As the company announced, net profit rose to just under 2.8 billion euros in the second quarter after a loss of 88.3 million euros in the same period of the previous year. For the first six months of this year, the surplus amounted to a good 3.9 billion euros after a loss of almost 142 million euros in the previous year. At the same time, the biopharmaceutical company raised the forecast for sales of its Covid-19 vaccine in the current year and now expects sales of the vaccine of 15.9 (previously: 12.4) billion euros. The sales expectation is based on the currently signed supply contracts for around 2.2 billion vaccine doses in 2021, as the Mainz-based company announced. "Additional sales are expected in connection with further supply contracts for deliveries in the year 2021, whereby the first contracts for 2022 and beyond have already been concluded," it said. According to BioNTech, production of three billion cans is now targeted by the end of the year. In 2022 it should then be up to four billion units. As of July 21, more than a billion vaccine doses had been delivered to more than 100 regions. US partner Pfizer had raised the sales forecast for the vaccine at the end of July after further supply contracts were concluded. Regarding a possible booster vaccination, the company said, "BioNTech and Pfizer believe that a booster or third dose of BNT162b2 has the potential to maintain the highest level of protection against all variants currently tested, including Delta." In the coming weeks, more precise data from the analysis of ongoing clinical studies will be published and submitted to the regulatory authorities in the USA, the European Union (EU) and other countries. On the US stock exchanges, the rally in mRNA vaccine stocks continues to know no bounds. The market value of Biontech now amounts to more than 100 billion dollars (84.2 billion euros). As the "New York Times" reported, the US health authority FDA intends to give final approval to the corona vaccine, which is marketed together with Pfizer, in September. So far it has only been an emergency approval. Biontech also wants to expand the company further. An extensive job creation is planned for the coming months, the company said, according to a report by "Welt am Sonntag". 500 new positions across all departments are currently advertised. Before the corona pandemic, Biontech employed a good 1,300 people. The company worked primarily on new therapies for cancer. Together with the US company Pfizer, Biontech then developed the first vaccine against the coronavirus approved in many countries last year.